Neurology Archives - Insights

Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing

Barbara J. Toman — Mon, 21 Oct 2024 13:15:00 +0000

Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.

The post Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing appeared first on Insights.

Plasma Test Increases Access to Alzheimer’s Testing: Alicia Algeciras-Schimnich, Ph.D.

Luci Gens — Thu, 10 Oct 2024 13:00:00 +0000

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Alicia Algeciras-Schimnich, Ph.D., a professor of laboratory medicine and pathology at Mayo Clinic and co-director of the Clinical Immunoassay Laboratory. They discuss Mayo Clinic’s plasma test for detecting Alzheimer’s disease and how […]

The post Plasma Test Increases Access to Alzheimer’s Testing: Alicia Algeciras-Schimnich, Ph.D. appeared first on Insights.

Innovative Alzheimer’s disease diagnostic tool unveiled

Luci Gens — Wed, 17 Apr 2024 12:00:00 +0000

Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative of amyloid beta accumulation in the brain. This test is set to transform the approach to Alzheimer's disease management, offering a convenient and less invasive alternative to traditional diagnostic methods.

The post Innovative Alzheimer’s disease diagnostic tool unveiled appeared first on Insights.

Noninvasive plasma biomarker testing provides faster answers: Alicia Algeciras-Schimnich, Ph.D.

Robin Huiras-Carlson — Tue, 09 Apr 2024 13:00:00 +0000

Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild cognitive impairment or early dementia. Positive test results can confirm amyloid beta pathology and facilitate access to disease-modifying therapies.

The post Noninvasive plasma biomarker testing provides faster answers: Alicia Algeciras-Schimnich, Ph.D. appeared first on Insights.

Unique collaboration advances discoveries for rare disease

Luci Gens — Tue, 24 Oct 2023 21:00:00 +0000

The nonprofit patient advocacy group called The MOG Project supports patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which is a rare and debilitating central nervous system demyelinating disorder. A team of Mayo Clinic neurologists, neuro-ophthalmologists, and the Autoimmune Neurology Laboratory at Mayo Clinic share a unique relationship with The MOG Project as they harness the power of patients’ experiences with MOGAD and their biospecimen data to advance the science behind this disease.

The post Unique collaboration advances discoveries for rare disease appeared first on Insights.